Updated Phase II data for Exelixis' cabozantinib

Exelixis Inc. (NASDAQ:EXEL) will present updated interim data from a Phase II trial of cabozantinib ( XL184) at the American Society of Clinical Oncology meeting in Chicago in June, according to an abstract released ahead of the meeting. In 51 evaluable patients in the cohort of subjects with advanced epithelial ovarian cancer, cabozantinib produced an overall response rate (ORR) of 24% at week 12, with five additional partial responses awaiting confirmation. The 12-week disease control rate (DCR) was 58%. At a median follow-up of four months, median progression-free survival and duration of response have not been reached. ...